X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Pfizer’s new partnership focuses on digitising clinical trials

    Pfizer Invests $120 Million in Biotechnology Innovation

    DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

    Pfizer and BioNTech Announce Agreement with the UK 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Pfizer’s new partnership focuses on digitising clinical trials

    Pfizer Invests $120 Million in Biotechnology Innovation

    DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

    Pfizer and BioNTech Announce Agreement with the UK 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

Content Team by Content Team
19th January 2021
in Drug Development, Manufacturing, Press Statements
Pfizer and BioNTech Announce Agreement with the UK 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

Baxter International announced Baxter BioPharma Solutions has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M™ adjuvant. Baxter BioPharma Solutions is a contract manufacturing organization that specializes in parenteral (injectable) pharmaceuticals, including vaccines. The agreement is expected to advance commercial-scale manufacturing essential for the vaccine’s production and distribution in the United Kingdom and European markets. Novavax’ COVID-19 vaccine candidate is currently in phase 3 trials and has not yet been authorized or approved for use.

“The quest to develop vaccines for COVID-19 has reinforced the opportunity for industry partners to work together and contribute their unique capabilities and expertise for the benefit of all,” said Marie Keeley, vice president, Baxter BioPharma Solutions. “We welcome the opportunity to work with an innovative company like Novavax and look forward to helping bring their vaccine candidate to the market.”

According to Novavax, NVX-CoV2373 contains a full-length, prefusion spike protein made using Novavax’ recombinant nanoparticle technology and the company’s proprietary saponin-based Matrix-M™ adjuvant. The purified protein is encoded by the genetic sequence of the SARS-CoV-2 spike (S) protein and is produced in insect cells. It can neither cause COVID-19 disease nor can it replicate, is stable at 2°C to 8°C and is manufactured in a ready-to-use liquid formulation that permits distribution using standard vaccine supply chain channels.

 

Our priority is to bring a safe, effective COVID-19 vaccine to people around the world,” said Rick Crowley, executive vice president, chief operations officer, Novavax. “Partners like Baxter BioPharma Solutions are enabling Novavax to quickly establish a commercial supply chain network to ensure access for global populations, and ultimately help bring about an end to the global COVID-19 pandemic.”

Baxter’s manufacturing services for NVX-CoV2373 will take place at its facility in Halle/Westfalen, Germany. The site has sterile manufacturing capabilities and areas of focus, offers current good manufacturing practices (cGMP) manufacturing with dedicated production areas and is designed to deliver products with optimum efficiency and speed to market.

About Baxter’s BioPharma Solutions BusinessBaxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise, sterile manufacturing solutions, parenteral delivery systems and customized support services needed to meet the unique challenges that parenteral products face. For more information, please visit www.baxterbiopharmasolutions.com.

About BaxterEveryday,millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products.For more than 85 years, we’ve beenoperating at the criticalintersection where innovations that save andsustainlivesmeet the healthcare providers thatmake it happen. With products, technologies andtherapies available in more than 100 countries, Baxter’s employees worldwide are nowbuilding upon the company’s richheritage of medical breakthroughs to advance thenext generation of transformative healthcare innovations. To learn more, visit www.baxter.comand follow us on Twitter,LinkedInandFacebook.

Previous Post

Brazil approves Sinovac and Astrazeneca Covid-19 vaccines for emergency use

Next Post

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Related Posts

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Clinical Trials

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

4th February 2021
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
Drug Development

GSK and CureVac to develop next generation mRNA COVID-19 vaccines

4th February 2021
Oxford leads first trial investigating dosing with alternating vaccines
Drug Development

Oxford leads first trial investigating dosing with alternating vaccines

4th February 2021
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
Drug Development

Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

28th January 2021
Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance
Drug Development

Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

28th January 2021
Brazil approves Sinovac and Astrazeneca Covid-19 vaccines for emergency use
Press Statements

Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs

28th January 2021
Next Post
Novartis sickle cell medicine Adakveo approved in Europe to prevent recurrent vaso-occlusive crises

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Latest News

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Clinical Trials

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

4th February 2021
CSafe Global to present new Parcel and Cell & Gene thermal shipping solutions
News

CSafe Global Continues Expansion Across Asia with Two New Hub Locations in China

4th February 2021
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
Drug Development

GSK and CureVac to develop next generation mRNA COVID-19 vaccines

4th February 2021
Oxford leads first trial investigating dosing with alternating vaccines
Drug Development

Oxford leads first trial investigating dosing with alternating vaccines

4th February 2021
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
Drug Development

Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

28th January 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In